BMS Breaks Ground on Bio-Plant

Bristol-Myers Squibb (BMS) says it has begun building a biologic drug manufacturing facility at Devens, MA. The facility is expected to cost about $750 million and is scheduled to start production in 2011, following regulatory approval in 2010. Final investment in the facility will total $1.1 billion, it says. The facility will feature six 20,000-liter cell culture reactor vessels and one purification line. It is being built primarily to manufacture BMS’s rheumatoid arthritis drug Orencia, which generated sales of $89 million in...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers